Healthcare >> CEO Interviews >> October 26, 2004

Marvin Hausman – Axonyx Inc (axyx)

Dr. MARVIN S. HAUSMAN has served as a Director and President and Chief Executive Officer of Axonyx, Inc., since January 1997. Dr. Hausman was a co-founder of Medco Research Inc., a pharmaceutical biotechnology company specializing in adenosine products. He has 30 years' experience in drug development and clinical care. Dr. Hausman received his medical degree from New York University School of Medicine in 1967 and has done residencies in General Surgery at Mt. Sinai Hospital in New York, and in Urological Surgery at U.C.L.A. Medical Center in Los Angeles. He also worked as a Research Associate at the National Institutes of Health, Bethesda, Maryland. He has been a lecturer, clinical instructor and attending surgeon at the U.C.L.A. Medical Center Division of Urology and Cedars-Sinai Medical Center, Los Angeles. He has been a Consultant on clinical/pharmaceutical research to various pharmaceutical companies, including Bristol-Meyers International, Mead-Johnson Pharmaceutical Company, Medco Research, Inc., and E.R. Squibb. Since October 1995 Dr. Hausman has been the President of Northwest Medical Research Partners, Inc., a medical technology and transfer company. Dr. Hausman served on the Board of Directors of Oxis International, Inc. from March 2002 to November 2003. The company currently owns approximately 53% of the outstanding common stock of Oxis. He was a member of the Board of Directors of Medco Research, Inc., from inception (1978) through 1992 and from May 1996 to July 1998. Dr Hausman was a member of the Board of Directors of Regent Assisted Living, Inc., a company specializing in building assisted living centers including care of senile dementia residents, from March 1996 to April 2001. In February he became a member of the Board of Directors of Arbios and in August 2004 rejoined the Board of Directors of Oxis. Profile
TWST: Give us a brief overview of what your company does and a brief


Dr. Hausman: Axonyx was formed in 1995-1996 with a mission statement to

develop drugs to treat cognitive disorders